| Name | Title | Contact Details |
|---|
Meda is a leading international specialty pharma company with a broad product portfolio reaching more than 80% of the global pharmaceutical market. Sales at the end of 2014 amounted to more than SEK 15 billion (pro forma SEK 18.7 billion). Meda is thereby the 48th largest pharmaceutical company in the world. At the end of 2014 Meda had 5,202 (3,326) employees, 2,996 (2,009) of which worked in sales and marketing. The company’s main focus is sales and marketing and Meda has its own sales organizations in more than 60 countries. Sales and marketing activities are carried out via distributors in countries where Meda has no representation and globally Meda’s products are sold in more than 150 countries.
Cobb Psychotherapy is a group private practice providing mental health counseling services. Our therapists practice a range of interventions including evidence-based therapies traditional talk therapy.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.
A physician led and owned organization committed to improving healthcare by supporting independent rheumatology practices across the nation and providing innovative technology to lower healthcare costs for providers and patients